The proposed bill aims to enhance transparency in healthcare by establishing a new section, 456.0525, in the Florida Statutes. This section defines "personal benefit" as any economic or non-economic advantage received by healthcare practitioners from pharmaceutical companies outside of the practitioner-patient relationship. It mandates that healthcare practitioners report any personal benefits to the Department of Health, with updates required at least quarterly. The reports must detail the nature, value, and purpose of the benefits received. Additionally, the Department is tasked with creating uniform reporting procedures and a publicly accessible online database to facilitate public access to this information.

Furthermore, the bill requires the Department to set guidelines for ethical practices when healthcare practitioners engage with pharmaceutical companies and mandates annual audits by the Auditor General to ensure compliance and accuracy of reported data. Violations of this section can lead to disciplinary actions by the relevant board, with repeated offenses classified as a first-degree misdemeanor. The bill is set to take effect on July 1, 2026.